Reliable Resources on Cannabinoid
Research and Clinical Development
HEALTHCARE PRACTITIONERS GUIDE
July 21, 2020
RHO PHYTO BY AVICANNA, HEALTHCARE PRACTITIONER GUIDE
This guide provides healthcare practitioners with information to make informed decisions about how to incorporate medical cannabis into their practice. It covers administration, dosing and titration guidance, potential side effects, warnings and precautions, and how to recommend RHO Phyto products. The purpose of this document is to provide medical information and not to serve as providing medical advice. Healthcare practitioners are responsible to exercise professional judgment when recommending the use of medical cannabis to their patients based on individual needs and circumstances. Any recommendations contained within this guide do not replace the clinical judgement of healthcare practitioners.
AVICANNA’S 3RD ANNUAL SYMPOSIUM SUMMARY
July 21, 2020
MEDICAL CANNABIS 2.0 – ADVANCEMENTS IN CANNABINOID RESEARCH, PRODUCT OFFERINGS AND PATIENT ACCESS
The 3rd annual Avicanna Symposium, “Medical Cannabis 2.0 – The Advancements in Cannabinoid Research, Product Offerings, and Patient Access”, was held virtually due to COVID-19 restrictions on the 21st of July, 2020. The purpose of the Symposium was to highlight the current state of advancements in the medical cannabis industry in Canada and abroad as well as underlining the key areas of research and product development. In addition, the speakers address patient access for medical cannabis products currently being offered on the market. This event brought together more than 1,000 participants including clinicians, researchers, regulatory affairs specialists, investors, members of the pharmaceutical industry and key representatives in the Canadian cannabis field.
AVICANNA’S 2ND ANNUAL SYMPOSIUM REVIEW
March 25, 2019
THE EMERGENCE OF BIOPHARMACEUTICAL CANNABINOIDS FROM RESEARCH & DEVELOPMENT TO CLINICAL TRANSLATION
The 2nd annual Avicanna Symposium, “The Emergence of Biopharmaceutical Cannabinoids – From Research & Development to Clinical Translation”, was held at the MaRS Discovery District (Canada’s premium launchpad for start-ups), Toronto, Canada on 25th March 2019. The Symposium was the first to be held in Canada by Avicanna, with the inaugural Symposium taking place in Santa Marta, Colombia, May 2018.
CANNABINOID APPLICATIONS IN DERMATOLOGY
Issue 1: March 2019
This is the first edition of our newsletter series, which will provide a range of bio-pharmaceutical topics and updates in the emerging field of cannabinoid research and clinical development. The objective of this newsletter is to create awareness of the latest and most significant cannabinoid-based research that is conducted worldwide, and available to the research community. Furthermore, we hope this newsletter serves to engage the medical and scientific community to continue building and fostering strong academic and clinical relationships.
CANNABINOID APPLICATIONS IN PAIN MANAGEMENT
Issue 2: April 2019
In this edition of our newsletter series, we focus on a recent publication that reviews the medical evidence for the treatment of chronic non-cancer pain (CNCP) with medical cannabis. This publication emphasizes the importance of interpreting the evidence of cannabis-based treatments towards specific CNCP, which aligns with Avicanna’s scientific and evidence-based approach for developing its cannabinoid-based products.
CANNABINOID APPLICATIONS IN EPILEPSY MANAGEMENT
Issue 3: June 2019
This newsletter explores cannabinoid applications in the treatment of epilepsy. Currently, there is significant evidence supporting medical cannabis as an adjunctive solution in epilepsy aside other treatments, however, there remains a paucity for research that proves cannabinoid-based therapies to be both independent and sustainable solutions to this disorder.